{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:29:17Z","timestamp":1790958557908,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>FLT3 tyrosine kinase inhibitor (TKI) therapy evolved into a standard therapy in FLT3-mutated AML. TKI resistance, however, develops frequently with poor outcomes. We analyzed acquired TKI resistance in AML cell lines by multilayered proteome analyses. Leupaxin (LPXN), a regulator of cell migration and adhesion, was induced during early resistance development, alongside the tyrosine kinase PTK2B which phosphorylated LPXN. Resistant cells differed in cell adhesion and migration, indicating altered niche interactions. PTK2B and LPXN were highly expressed in leukemic stem cells in FLT3-ITD patients. PTK2B\/FAK inhibition abrogated resistance-associated phenotypes, such as enhanced cell migration. Altered pathways in resistant cells, assessed by nascent proteomics, were largely reverted upon PTK2B\/FAK inhibition. PTK2B\/FAK inhibitors PF-431396 and defactinib synergized with different TKIs or daunorubicin in FLT3-mutated AML. Midostaurin-resistant and AML cells co-cultured with mesenchymal stroma cells responded particularly well to PTK2B\/FAK inhibitor addition. Xenograft mouse models showed significant longer time to leukemia symptom-related endpoint upon gilteritinib\/defactinib combination treatment in comparison to treatment with either drug alone. Our data suggest that the leupaxin-PTK2B axis plays an important role in acquired TKI resistance in AML. PTK2B\/FAK inhibitors act synergistically with currently used therapeutics and may overcome emerging TKI resistance in FLT3-mutated AML at an early timepoint.<\/jats:p>","DOI":"10.1038\/s41375-022-01687-x","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T18:04:03Z","timestamp":1662141843000},"page":"2418-2429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML"],"prefix":"10.1038","volume":"36","author":[{"given":"Catana","family":"Allert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Waclawiczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Miriam Naomi","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"G\u00f6llner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Heid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Renders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Bruckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Zinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Besenbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wickenhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Trumpp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7549-9326","authenticated-orcid":false,"given":"Jeroen","family":"Krijgsveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7524-4080","authenticated-orcid":false,"given":"Maximilian Felix","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"1687_CR1","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752\u20139.","journal-title":"Blood"},{"key":"1687_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N. Engl J Med. 2017;377:454\u201364.","journal-title":"N. Engl J Med"},{"key":"1687_CR3","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N. Engl J Med. 2019;381:1728\u201340.","journal-title":"N. Engl J Med"},{"key":"1687_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S0301-472X(01)00612-9","volume":"29","author":"SM Garrido","year":"2001","unstructured":"Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol. 2001;29:448\u201357.","journal-title":"Exp Hematol"},{"key":"1687_CR5","doi-asserted-by":"publisher","first-page":"592733","DOI":"10.3389\/fonc.2020.592733","volume":"10","author":"HN Kim","year":"2020","unstructured":"Kim HN, Ruan Y, Ogana H, Kim YM. Cadherins, selectins, and integrins in CAM-DR in leukemia. Front Oncol. 2020;10:592733.","journal-title":"Front Oncol"},{"key":"1687_CR6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.leukres.2014.03.007","volume":"38","author":"S Qiu","year":"2014","unstructured":"Qiu S, Jia Y, Xing H, Yu T, Yu J, Yu P, et al. N-Cadherin and Tie2 positive CD34(+)CD38(-)CD123(+) leukemic stem cell populations can develop acute myeloid leukemia more effectively in NOD\/SCID mice. Leuk Res. 2014;38:632\u20137.","journal-title":"Leuk Res"},{"key":"1687_CR7","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/ar.23345","volume":"299","author":"L Zhi","year":"2016","unstructured":"Zhi L, Gao Y, Yu C, Zhang Y, Zhang B, Yang J, et al. N-cadherin aided in maintaining the characteristics of leukemic stem cells. Anat Rec. 2016;299:990\u20138.","journal-title":"Anat Rec"},{"key":"1687_CR8","doi-asserted-by":"publisher","first-page":"13591","DOI":"10.18632\/oncotarget.3792","volume":"6","author":"S Dierks","year":"2015","unstructured":"Dierks S, von Hardenberg S, Schmidt T, Bremmer F, Burfeind P, Kaulfuss S. Leupaxin stimulates adhesion and migration of prostate cancer cells through modulation of the phosphorylation status of the actin-binding protein caldesmon. Oncotarget 2015;6:13591\u2013606.","journal-title":"Oncotarget"},{"key":"1687_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3892\/ijo.2015.2988","volume":"47","author":"S Kaulfuss","year":"2015","unstructured":"Kaulfuss S, Herr AM, Buchner A, Hemmerlein B, Gunthert AR, Burfeind P. Leupaxin is expressed in mammary carcinoma and acts as a transcriptional activator of the estrogen receptor alpha. Int J Oncol. 2015;47:106\u201314.","journal-title":"Int J Oncol"},{"key":"1687_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13046-019-1221-0","volume":"38","author":"SI Al-Juboori","year":"2019","unstructured":"Al-Juboori SI, Vadakekolathu J, Idri S, Wagner S, Zafeiris D, Pearson JR, et al. PYK2 promotes HER2-positive breast cancer invasion. J Exp Clin Cancer Res. 2019;38:210.","journal-title":"J Exp Clin Cancer Res"},{"key":"1687_CR11","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J 2015;13:504\u201313.","journal-title":"Comput Struct Biotechnol J"},{"key":"1687_CR12","doi-asserted-by":"publisher","first-page":"S1672-0229(22)0","DOI":"10.1016\/j.gpb.2022.01.004","volume":"24","author":"S Zheng","year":"2015","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets. Genom Proteom Bioinform. 2022,24;S1672-0229(22)00008-0. https:\/\/doi.org\/10.1016\/j.gpb.2022.01.004. Online ahead of print.","journal-title":"Genom Proteom Bioinform"},{"key":"1687_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18504-7","volume":"11","author":"N Gremke","year":"2020","unstructured":"Gremke N, Polo P, Dort A, Schneikert J, Elmshauser S, Brehm C, et al. mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. Nat Commun. 2020;11:4684.","journal-title":"Nat Commun"},{"key":"1687_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01143-3","volume":"11","author":"G Obeng","year":"2021","unstructured":"Obeng G, Park EJ, Appiah MG, Kawamoto E, Gaowa A, Shimaoka M. miRNA-200c-3p targets talin-1 to regulate integrin-mediated cell adhesion. Sci Rep. 2021;11:21597.","journal-title":"Sci Rep"},{"key":"1687_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3892\/ijmm.2022.5116","volume":"49","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Lykov N, Tzeng C. Talin1 interaction network in cellular mechanotransduction (Review). Int J Mol Med. 2022;49:60.","journal-title":"Int J Mol Med"},{"key":"1687_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep18491","volume":"5","author":"J Qu","year":"2015","unstructured":"Qu J, Ero R, Feng C, Ong LT, Tan HF, Lee HS, et al. Kindlin-3 interacts with the ribosome and regulates c-Myc expression required for proliferation of chronic myeloid leukemia cells. Sci Rep. 2015;5:18491.","journal-title":"Sci Rep"},{"key":"1687_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nm.4247","volume":"23","author":"S Gollner","year":"2017","unstructured":"Gollner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med. 2017;23:69\u201378.","journal-title":"Nat Med"},{"key":"1687_CR18","doi-asserted-by":"publisher","first-page":"11709","DOI":"10.1074\/jbc.273.19.11709","volume":"273","author":"BP Lipsky","year":"1998","unstructured":"Lipsky BP, Beals CR, Staunton DE. Leupaxin is a novel LIM domain protein that forms a complex with PYK2. J Biol Chem. 1998;273:11709\u201313.","journal-title":"J Biol Chem"},{"key":"1687_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature24294","volume":"551","author":"S Raffel","year":"2017","unstructured":"Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, et al. BCAT1 restricts alphaKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature 2017;551:384\u20138.","journal-title":"Nature"},{"key":"1687_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-021-00233-2","volume":"10","author":"Y Yao","year":"2021","unstructured":"Yao Y, Li F, Huang J, Jin J, Wang H. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development. Exp Hematol Oncol. 2021;10:39.","journal-title":"Exp Hematol Oncol"},{"key":"1687_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3389\/fcell.2020.00607","volume":"8","author":"A Villatoro","year":"2020","unstructured":"Villatoro A, Konieczny J, Cuminetti V, Arranz L. Leukemia Stem cell release from the stem cell niche to treat acute myeloid leukemia. Front Cell Dev Biol. 2020;8:607.","journal-title":"Front Cell Dev Biol"},{"key":"1687_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","volume":"139","author":"DE Gerber","year":"2020","unstructured":"Gerber DE, Camidge DR, Morgensztern D, Cetnar J, Kelly RJ, Ramalingam SS, et al. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer. 2020;139:60\u20137.","journal-title":"Lung Cancer"},{"key":"1687_CR23","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3390\/cancers14071600","volume":"14","author":"TA Burley","year":"2022","unstructured":"Burley TA, Hesketh A, Bucca G, Kennedy E, Ladikou EE, Towler BP, et al. Elucidation of focal adhesion kinase as a modulator of migration and invasion and as a potential therapeutic target in chronic lymphocytic leukemia. Cancers. 2022;14:1600.","journal-title":"Cancers"},{"key":"1687_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bjh.12599","volume":"164","author":"X Yang","year":"2014","unstructured":"Yang X, Sexauer A, Levis M. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br J Haematol. 2014;164:61\u201372.","journal-title":"Br J Haematol"},{"key":"1687_CR25","first-page":"135","volume":"17","author":"GH Zhu","year":"2019","unstructured":"Zhu GH, Dai HP, Shen Q, Zhang Q. Downregulation of LPXN expression by siRNA decreases the malignant proliferation and transmembrane invasion of SHI-1 cells. Oncol Lett. 2019;17:135\u201340.","journal-title":"Oncol Lett"},{"key":"1687_CR26","first-page":"10","volume":"2018","author":"V Pallares","year":"2018","unstructured":"Pallares V, Hoyos M, Chillon MC, Barragan E, Prieto Conde MI, Llop M, et al. Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. Cancers. 2018;10:436.","journal-title":"Cancers"},{"key":"1687_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1600-0609.2010.01556.x","volume":"86","author":"A Katsumi","year":"2011","unstructured":"Katsumi A, Kiyoi H, Abe A, Tanizaki R, Iwasaki T, Kobayashi M, et al. FLT3\/ ITD regulates leukaemia cell adhesion through alpha4beta1 integrin and Pyk2 signalling. Eur J Haematol. 2011;86:191\u20138.","journal-title":"Eur J Haematol"},{"key":"1687_CR28","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1210\/en.2019-00237","volume":"160","author":"AY Sato","year":"2019","unstructured":"Sato AY, Cregor M, McAndrews K, Li T, Condon KW, Plotkin LI, et al. Glucocorticoid-induced bone fragility is prevented in female mice by blocking Pyk2\/Anoikis signaling. Endocrinology 2019;160:1659\u201373.","journal-title":"Endocrinology"},{"key":"1687_CR29","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","volume":"33","author":"SF Jones","year":"2015","unstructured":"Jones SF, Siu LL, Bendell JC, Cleary JM, Razak AR, Infante JR, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest N. Drugs. 2015;33:1100\u20137.","journal-title":"Invest N. Drugs"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01687-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01687-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01687-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T19:13:11Z","timestamp":1664478791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01687-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1687"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01687-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"assertion":[{"value":"23 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}